For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Govt to Shed 28 Bil. Yen via Huge Seller Drugs, 20 Bil. Yen via Existing Re-Pricing Rule; Physicians to Win “Plus” Revision
December 21, 2015
- Shipments of Kaketsuken’s Hep B Vaccine Likely to Resume Early Next Year
December 18, 2015
- MHLW to Carefully Discuss Cost Effectiveness of Prevenar 13 for Its Elderly Use under National Program
December 18, 2015
- ICH Reaches Agreement to Treat Subjects with Similar Ethnic Factors as Single Populations Regardless of Nationality
December 18, 2015
- PMDA Beating Targets for Overall Review Time in FY2015
December 18, 2015
- Chuikyo Approves Plan to Introduce Cost-Effective Assessments on Trial Basis; Selection of Products to Begin Next April
December 17, 2015
- Premium for Sakigake Products Clears Chuikyo Subcommittee
December 17, 2015
- Survey Finds Unexpectedly Low Market Prices for Injectable Generics; Industry to Accept 50% Rule
December 17, 2015
- Chuikyo Subcommittee OKs Outline of FY2016 Drug Pricing Reform, Rollout of “Huge Seller” Re-Pricing
December 17, 2015
- PMDA Plans to Increase Inspection Staff in Response to Kaketsuken Scandal
December 17, 2015
- Japan to Draw Up Action Plan on Drug Resistance: Health Minister
December 16, 2015
- MHLW to Establish Task Force in Response to Scandal at Kaketsuken
December 16, 2015
- Diet Submission of Clinical Research Bill Expected for Next Year: Panel Member
December 15, 2015
- More than 10 Regenerative Medicine Products Seeking Sakigake Designation: MHLW Official
December 15, 2015
- Chuikyo Discusses Optimizing Health Coverage for Poultices, Vitamins
December 14, 2015
- PMDA Reviewing Use of Ofev in Patients with Liver Dysfunction
December 14, 2015
- LDP OKs Taxation Changes for FY2016; R&D Tax Credit to Remain Intact
December 11, 2015
- 6 Drug Makers to Participate in AMED’s Drug Discovery Consortium
December 11, 2015
- First Generics for Jzoloft, Other Brands to Join NHI Price List on Dec. 11
December 10, 2015
- 3 Trade Groups Vehemently Oppose “Huge Seller” Drug Re-Pricing, Say It Will Hobble Innovation
December 10, 2015
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…